Device type · KLS
Enzyme Immunoassay, Theophylline
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
KLS
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Theophylline
- Product code
- KLS
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3880
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for KLS
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Siemens Healthcare Diagnostics, Inc.
Z-1946-2018 · Started Nov 27, 2017
Reason given: Lot J1 of the Syva EMIT 2000 Theophylline Assay, when run on a Beckman AU Clinical Chemistry System, may exhibit increased imprecision for commercially available controls and for patient samples.
Cause as FDA categorized it: Nonconforming Material/Component
Siemens Healthcare Diagnostics, Inc.
Z-2298-2016 · Started Jun 17, 2016 · Posted by FDA Jul 28, 2016
Reason given: Siemens Healthcare Diagnostics has confirmed the Syva EMIT 2000 Theophylline reagent lot G3, when run on a Beckman AU Clinical Chemistry System, and the ADVIA Chemistry Theophylline_2 (THEO_2) reagent lot 334018, may exhibit increased imprecision for commercially available Bio-Rad Liquichek TDM Quality Control Levels...
Cause as FDA categorized it: Process control
Siemens Healthcare Diagnostics, Inc.
Z-2299-2016 · Started Jun 17, 2016 · Posted by FDA Jul 28, 2016
Reason given: Siemens Healthcare Diagnostics has confirmed the Syva EMIT 2000 Theophylline reagent lot G3, when run on a Beckman AU Clinical Chemistry System, and the ADVIA Chemistry Theophylline_2 (THEO_2) reagent lot 334018, may exhibit increased imprecision for commercially available Bio-Rad Liquichek TDM Quality Control Levels...
Cause as FDA categorized it: Process control
5 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.